194 related articles for article (PubMed ID: 17891370)
21. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
[TBL] [Abstract][Full Text] [Related]
22. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
J Nucl Med Technol; 2010 Mar; 38(1):6-17. PubMed ID: 20197541
[TBL] [Abstract][Full Text] [Related]
24. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations.
Huellner MW; Appenzeller P; Kuhn FP; Husmann L; Pietsch CM; Burger IA; Porto M; Delso G; von Schulthess GK; Veit-Haibach P
Radiology; 2014 Dec; 273(3):859-69. PubMed ID: 25102372
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study.
Schwenzer NF; Schraml C; Müller M; Brendle C; Sauter A; Spengler W; Pfannenberg AC; Claussen CD; Schmidt H
Radiology; 2012 Aug; 264(2):551-8. PubMed ID: 22653189
[TBL] [Abstract][Full Text] [Related]
26. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.
Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC
Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492
[TBL] [Abstract][Full Text] [Related]
27. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
[TBL] [Abstract][Full Text] [Related]
28. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
29. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
30. [Whole-body diffusion-weighted magnetic resonance imaging in oncology].
Jouvet JC; Thomson V; Durupt F; Bakir M; Berthezene Y
Presse Med; 2010 May; 39(5):548-52. PubMed ID: 19932000
[TBL] [Abstract][Full Text] [Related]
31. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.
Yi CA; Shin KM; Lee KS; Kim BT; Kim H; Kwon OJ; Choi JY; Chung MJ
Radiology; 2008 Aug; 248(2):632-42. PubMed ID: 18552311
[TBL] [Abstract][Full Text] [Related]
32. [Whole-body tumor staging: MRI or FDG-PET/CT?].
Antoch G; Vogt FM; Bockisch A; Ruehm SG
Radiologe; 2004 Sep; 44(9):882-8. PubMed ID: 15349729
[TBL] [Abstract][Full Text] [Related]
33. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
[TBL] [Abstract][Full Text] [Related]
36. Prospective observational study on diagnostic accuracy of whole-body MRI in solid small round cell tumours.
Kembhavi SA; Rangarajan V; Shah S; Qureshi S; Arora B; Juvekar S; Laskar S; Vora T; Chinnaswamy G; Ramadwar M; Kurkure P
Clin Radiol; 2014 Sep; 69(9):900-8. PubMed ID: 24863003
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?
Langer A
BMC Health Serv Res; 2010 Oct; 10():283. PubMed ID: 20932288
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
39. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
[TBL] [Abstract][Full Text] [Related]
40. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
